INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 169 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2016. The put-call ratio across all filers is 1.85 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $3,665,000 | +26.8% | 30,274 | +18.5% | 0.02% | +53.8% |
| Q1 2017 | $2,890,000 | +13.7% | 25,550 | +9.2% | 0.01% | 0.0% |
| Q4 2016 | $2,541,000 | -37.7% | 23,389 | -5.6% | 0.01% | -31.6% |
| Q3 2016 | $4,079,000 | -7.6% | 24,781 | -19.9% | 0.02% | -17.4% |
| Q2 2016 | $4,415,000 | -10.4% | 30,946 | -19.3% | 0.02% | -30.3% |
| Q1 2016 | $4,929,000 | -27.8% | 38,369 | -16.1% | 0.03% | -38.9% |
| Q4 2015 | $6,829,000 | +1.5% | 45,728 | +12.7% | 0.05% | +3.8% |
| Q3 2015 | $6,727,000 | -48.2% | 40,558 | -24.6% | 0.05% | -32.5% |
| Q2 2015 | $12,976,000 | +50.5% | 53,759 | +75.9% | 0.08% | +54.0% |
| Q1 2015 | $8,620,000 | +92.2% | 30,566 | +6.3% | 0.05% | +78.6% |
| Q4 2014 | $4,485,000 | -48.8% | 28,750 | -22.3% | 0.03% | -39.1% |
| Q3 2014 | $8,755,000 | -1.1% | 36,988 | -1.1% | 0.05% | +12.2% |
| Q2 2014 | $8,852,000 | -7.9% | 37,407 | +28.3% | 0.04% | -14.6% |
| Q1 2014 | $9,615,000 | – | 29,155 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |